J&J’s Drug Pipeline Not Strong Enough to Accelerate Growth
July 14, 2015 at 12:30 PM EDT
Increasing commotion over its branded drugs and a device segment that seems to lack innovation will hold back J&J’s revenue growth in the coming years.